Related Experiment Video
Updated: May 15, 2026

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
Published on: July 4, 2007
A case of natalizumab-associated progressive multifocal leukoencephalopathy with repeated negative CSF JCV testing
Monica E Mazda1, Jared R Brosch, Andrea L Wiens
1Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 46202, USA. monicamazda@gmail.com
Abstract:
The development of progressive multifocal leukoencephalopathy (PML) in patients treated with natalizumab is a well-known potential risk. Diagnosis of PML can be confounded in patients with multiple sclerosis (MS) if new demyelinating lesions develop, and the sensitivity of existing diagnostic tests is less than ideal. In the case presented here, four samples of cerebrospinal fluid tested negative for John Cunningham virus (JCV) DNA by polymerase chain reaction, yet brain biopsy eventually proved positive by immunohistochemistry. A review of the limitations of existing clinical diagnostic tests is addressed, and we review the most recent literature on the proper management of natalizumab-treated MS patients.
Insights
Progressive multifocal leukoencephalopathy (PML) can occur in natalizumab-treated patients. Diagnostic tests for PML, like JCV DNA PCR, may be insensitive, necessitating further investigation like brain biopsy.
Area of Science:
- Neuroimmunology
- Viral Pathogenesis
Background:
- Natalizumab is an effective treatment for multiple sclerosis (MS).
- Progressive multifocal leukoencephalopathy (PML) is a rare but serious risk associated with natalizumab therapy.
- Demyelinating lesions in MS can mimic PML, complicating diagnosis.
Observation:
- A case where cerebrospinal fluid (CSF) testing for John Cunningham virus (JCV) DNA via PCR was negative.
- Brain biopsy ultimately confirmed PML via immunohistochemistry despite negative CSF PCR results.
Findings:
- Current diagnostic methods for PML, including JCV DNA PCR in CSF, may have limitations in sensitivity.
- Immunohistochemistry on brain biopsy is a definitive diagnostic tool for PML.
Implications:
- The findings highlight the need for careful clinical monitoring of natalizumab-treated MS patients for PML.
- Alternative diagnostic strategies may be required when CSF PCR is negative but clinical suspicion for PML is high.
- This underscores the importance of considering definitive diagnostic procedures when faced with ambiguous cases.
Related Concept Videos
Arboviral Encephalitis
Cytomegalovirus Disease
Encephalitis ll: Pathophysiology
Encephalitis l: Introduction
Viral Meningitis
Multiple Sclerosis l: Introduction
